CHMP Backs Celgene's Pomalyst - Analyst Blog

By
A A A

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) recently issued a positive opinion regarding the approval of Celgene Corporation 's ( CELG ) oncology drug, Pomalyst.

Celgene is seeking approval for the use of Pomalyst in combination with low-dose dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM) patients, who have received at least two prior therapies (inclusive of Celgene's key oncology drug Revlimid and Takeda Pharmaceutical Company' s ( TKPYY ) Velcade). The disease worsened for the patients while on their last therapy. A final decision from the European Commission is expected within two to three months.

The CHMP's positive opinion on Pomalyst came on the back of encouraging data from the phase III study (MM-003: n=455). The study evaluated Pomalyst as a combination therapy in relapsed refractory multiple myeloma patients. Data revealed that there was significant improvement in progression-free survival and overall survival in patients in the Pomalyst arm.

We note that Pomalyst is already available in the US for the MM indication. The US Food and Drug Administration approved Pomalyst in Feb 2013. The US approval of Pomalyst has boosted Celgene's already strong oncology product portfolio. Celgene's top line would be boosted further in the event of Pomalyst gaining EU approval as the MM market offers significant commercial potential.  

Celgene, a biopharmaceutical company, currently carries a Zacks Rank #2 (Buy). Alexion Pharmaceuticals, Inc. ( ALXN ) appears to be equally attractive in the biopharma space with an identical rank. Santarus, Inc. ( SNTS ), a specialty biopharmaceutical company, carries a Zacks Rank #1 (Strong Buy).



ALEXION PHARMA (ALXN): Free Stock Analysis Report

CELGENE CORP (CELG): Free Stock Analysis Report

SANTARUS INC (SNTS): Free Stock Analysis Report

TAKEDA PHARMACT (TKPYY): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ALXN , CELG , CHMP , MM , SNTS

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

24,912,868
  • $102.4289 ▲ 0.29%
23,885,059
  • $16.05 ▼ 0.93%
17,155,013
  • $49.78 ▲ 3.58%
16,767,801
  • $13.08 ▼ 4.39%
10,895,208
  • $19.12 ▼ 0.47%
10,772,874
  • $3.605 ▲ 0.42%
10,013,950
  • $10.8799 ▼ 2.86%
9,474,397
  • $74.13 ▼ 0.67%
As of 8/28/2014, 11:07 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com